ATAI Life Sciences NV
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ATAI Life Sciences' stock with a target price of $6.78, indicating growth potential.
Financial Health
ATAI Life Sciences is generating modest revenue and cash flow, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ATAI
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline diversity
ATAI funds multiple programmes across different mechanisms, which can spread scientific risk — though individual trials still carry binary outcomes and uncertainty.
Clinical catalysts ahead
Upcoming trial readouts and regulatory steps could materially affect the stock; these events offer potential opportunity but also volatility.
Market and regulation
Growing interest in mental-health therapeutics supports investor attention, yet regulatory change and funding needs remain key risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
